Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A First in man, Phase 1 study of QN-01 for healthy adults

Next Previous
X
Search
Trial Profile

A First in man, Phase 1 study of QN-01 for healthy adults

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Dec 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs QN 01 (Primary)
  • Indications Smoking withdrawal
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors Qnovia

    • Most Recent Events

    • 29 Nov 2023 Positive initial results from this study presented in a Qnovia media release.
    • 29 Nov 2023 According to a Qnovia media release, QN-01 is an inhaled smoking cessation therapy that is currently being evaluated in the U.S. under FDAs Center for Drug Evaluation and Research (CDER) and in the U.K. by the Medicines and Healthcare Products Regulatory Agency (MHRA).
    • 06 Oct 2022 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top